J Sieper Selected Research

infliximab (Remicade)

03/2008	Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice.
03/2008	Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
09/2007	Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.
02/2006	Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
12/2005	Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
10/2005	Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
08/2005	Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
08/2005	Infliximab for the treatment of ankylosing spondylitis.
05/2005	Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
02/2005	Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
10/2004	[Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]
08/2003	Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
04/2003	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
11/2002	Infliximab in the treatment of active and severe ankylosing spondylitis.
04/2002	Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
12/2001	Infliximab treatment of severe ankylosing spondylitis: one-year followup.
06/2000	Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.

Articles by Research Topic

Disease

41	Ankylosing Spondylitis 03/2008 - 06/2000
7	Necrosis 03/2008 - 04/2000
4	Rheumatoid Arthritis 07/2003 - 04/2000
3	Reactive Arthritis (Reiter Disease) 06/2002 - 02/2000
2	Osteoarthritis 06/2002 - 11/2000
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2007
1	Back Pain (Backache) 09/2006
1	Inflammation 12/2005
1	Anterior Uveitis 08/2005
1	Connective Tissue Diseases (Connective Tissue Disease) 01/2002
1	Mixed Connective Tissue Disease (MCTD) 01/2002
1	Syndrome 01/2002

Drug/Important Bio-Agent (IBA)

17	infliximab (Remicade)FDA Link 03/2008 - 06/2000
9	TNFR-Fc fusion protein (etanercept)FDA Link 12/2006 - 06/2003
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2007 - 06/2000
3	Methotrexate (Mexate)FDA LinkGeneric 03/2007 - 04/2000
3	AntigensIBA 06/2002 - 12/2000
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 09/2006 - 04/2002
2	Aggrecans (Aggrecan)IBA 05/2005 - 07/2003
1	celecoxib (Celebrex)FDA Link 03/2008
1	Diclofenac (SR 38)FDA LinkGeneric 03/2008
1	Transforming Growth Factor beta (TGF-beta)IBA 06/2006
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2005
1	leflunomide (Arava)FDA LinkGeneric 01/2005
1	pamidronate (APD)FDA LinkGeneric 08/2003
1	Interferon-gamma (Interferon, gamma)IBA 06/2003
1	HLA-DRB1 antigen (HLA DRB1)IBA 06/2002
1	Prednisolone (Predate)FDA LinkGeneric 01/2002
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2002
1	Carbon MonoxideIBA 01/2002
1	RadiumIBA 04/2001
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2001
1	Interleukin-1 (Interleukin 1)IBA 11/2000
1	Interleukin-1beta (Interleukin 1 beta)IBA 11/2000
1	AntibodiesIBA 11/2000
1	Interleukin-10 (Interleukin 10)IBA 04/2000
1	Interleukin-4 (Interleukin 4)IBA 04/2000
1	Chaperonin 60IBA 02/2000